Cargando…
BRAF Targets in Melanoma Biological Mechanisms, Resistance, and Drug Discovery /
This volume contains a collection of writings from the leaders in the fields of Molecular Biology and Melanoma Research which will begin to tell the ever-expanding story of the most recent findings, discoveries, and potential of BRAF-directed targets in melanoma. Recent research has shown that BRAF...
| Clasificación: | Libro Electrónico |
|---|---|
| Autor Corporativo: | |
| Otros Autores: | |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
New York, NY :
Springer New York : Imprint: Humana,
2015.
|
| Edición: | 1st ed. 2015. |
| Colección: | Cancer Drug Discovery and Development,
82 |
| Temas: | |
| Acceso en línea: | Texto Completo |
MARC
| LEADER | 00000nam a22000005i 4500 | ||
|---|---|---|---|
| 001 | 978-1-4939-2143-0 | ||
| 003 | DE-He213 | ||
| 005 | 20220118095616.0 | ||
| 007 | cr nn 008mamaa | ||
| 008 | 141124s2015 xxu| s |||| 0|eng d | ||
| 020 | |a 9781493921430 |9 978-1-4939-2143-0 | ||
| 024 | 7 | |a 10.1007/978-1-4939-2143-0 |2 doi | |
| 050 | 4 | |a RC261-271 | |
| 072 | 7 | |a MJCL |2 bicssc | |
| 072 | 7 | |a MED062000 |2 bisacsh | |
| 072 | 7 | |a MJCL |2 thema | |
| 082 | 0 | 4 | |a 571.978 |2 23 |
| 082 | 0 | 4 | |a 616.994 |2 23 |
| 245 | 1 | 0 | |a BRAF Targets in Melanoma |h [electronic resource] : |b Biological Mechanisms, Resistance, and Drug Discovery / |c edited by Ryan J. Sullivan. |
| 250 | |a 1st ed. 2015. | ||
| 264 | 1 | |a New York, NY : |b Springer New York : |b Imprint: Humana, |c 2015. | |
| 300 | |a VIII, 204 p. 26 illus., 21 illus. in color. |b online resource. | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 347 | |a text file |b PDF |2 rda | ||
| 490 | 1 | |a Cancer Drug Discovery and Development, |x 2196-9914 ; |v 82 | |
| 505 | 0 | |a Melanoma: Historical Context -- Melanoma Pathogenesis -- Molecular Diagnostics and Tumor Mutational Analysis -- Clinical Utility of BRAF-targeted therapy in Melanoma -- The Ethics of Randomized Trials in Oncology -- Parallel and Serial Blockade Strategies in BRAF-Mutant Melanoma -- Targeting the cell cycle and p53 in combination with BRAF-directed therapy -- Combination BRAF-directed therapy and immunotherapy -- Moving Forward: Making BRAF-Targeted Therapy Better. | |
| 520 | |a This volume contains a collection of writings from the leaders in the fields of Molecular Biology and Melanoma Research which will begin to tell the ever-expanding story of the most recent findings, discoveries, and potential of BRAF-directed targets in melanoma. Recent research has shown that BRAF inhibitors are effective for a short period of time, but there is little hope that these drugs as single agents will lead to durable benefit in a majority of patients. Among scientists and researchers who work in drug discovery, there is a lot of interest in the development of molecularly targeted cancer agents. Namely, the identification of a molecular target, the selection of molecules which effectively inhibit this target. What is starkly different about the development of this class of compounds, however, is that the mechanism of action of these agents are not as straightforward as was once previously assumed and the mechanisms of resistance that tumor cells employ to evade complete destruction are unlike any that have been described before. These discoveries in addition to utilization of modern molecular biology techniques have led to a series of hypotheses regarding which other types of molecules could be used in combination with BRAF-inhibitors in hopes of revolutionizing the potential of therapeutics in melanoma. | ||
| 650 | 0 | |a Cancer. | |
| 650 | 0 | |a Medicine-Research. | |
| 650 | 0 | |a Biology-Research. | |
| 650 | 0 | |a Medical microbiology. | |
| 650 | 0 | |a Pharmacology. | |
| 650 | 1 | 4 | |a Cancer Biology. |
| 650 | 2 | 4 | |a Biomedical Research. |
| 650 | 2 | 4 | |a Medical Microbiology. |
| 650 | 2 | 4 | |a Pharmacology. |
| 700 | 1 | |a Sullivan, Ryan J. |e editor. |4 edt |4 http://id.loc.gov/vocabulary/relators/edt | |
| 710 | 2 | |a SpringerLink (Online service) | |
| 773 | 0 | |t Springer Nature eBook | |
| 776 | 0 | 8 | |i Printed edition: |z 9781493921447 |
| 776 | 0 | 8 | |i Printed edition: |z 9781493921423 |
| 776 | 0 | 8 | |i Printed edition: |z 9781493953486 |
| 830 | 0 | |a Cancer Drug Discovery and Development, |x 2196-9914 ; |v 82 | |
| 856 | 4 | 0 | |u https://doi.uam.elogim.com/10.1007/978-1-4939-2143-0 |z Texto Completo |
| 912 | |a ZDB-2-SME | ||
| 912 | |a ZDB-2-SXM | ||
| 950 | |a Medicine (SpringerNature-11650) | ||
| 950 | |a Medicine (R0) (SpringerNature-43714) | ||